Margetuximab conjugated-PEG-PAMAM G4 nano-complex: a smart nano-device for suppression of breast cancer

Khakinahad, Yasaman; Sohrabi, Saeedeh; Razi, Shokufeh; Narmani, Asghar; Khaleghi, Sepideh; Asadiyun, Mahboubeh; Jafari, Hanieh; Mohammadnejad, Javad

doi:10.1007/s13534-022-00225-z

Cited by 25 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The toxic impact of samples, including, PLGA, PLGA‐Alg, FA‐PLGA‐Alg, FA‐PLGA‐Dox‐Alg, PLGA‐Alg‐Dox, PLGA‐Dox, and pure Dox, on HepG2, Huh7, and HGF cells was surveyed after 24 h, 48 h, and 72 h of treatment with 50 nM, 100 nM, 200 nM, and 400 nM concentrations using the MTT assay [32]. Briefly, the synthesised samples were prepared in a serum‐supplemented tissue culture medium and sterilised by 0.2 μm filtration at pH 7.4.…”

Section: Methodsmentioning

confidence: 99%

Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells

Hoseinzadeh

Mokhtari

Kafilzadeh

et al. 2023

IET Nanobiotechnology

Self Cite

View full text Add to dashboard Cite

Efficient drug delivery systems (DDSs) can potentially replace with conventional modalities in cancer therapy, like liver cancer. In this study, a novel folic acid (FA)‐functionalised and alginate (Alg)‐modified poly lactic‐co‐glycolic acid (PLGA) nanocomposite was developed for delivery of doxorubicin (Dox) to HepG2 and Huh7 liver cancer cells. After synthesising the nanocarrier, several analytical devices, including FT‐IR, DLS, TGA, and TEM, were employed for its characterisation. Nano‐metric size (55 and 85 nm in diameter), close to neutral surface charge, semi‐spherical morphology, and successful synthesis were approved. Dox entrapment efficiency was determined near 1%, and sustained and pH‐sensitive drug release behaviours of nanocarrier were ascertained for DDS. Afterwards, the cell viability test was carried out to study the HepG2 and Huh7 cells suppression capability of FA‐PLGA‐Dox‐Alg. About 12% and 10% cell viabilities were observed in HepG2 and Huh7 cancer cells after 24 h treatment with 400 nM concentration of FA‐PLGA‐Dox‐Alg nanocarrier respectively. The IC50 value was observed for 100 nM after 24 h of treatment in cancer cells. These data have indicated that fabricated nanocarrier could be promising DDS against liver cancer and replace with conventional approaches in cancer treatment, like chemotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells

Hoseinzadeh

Mokhtari

Kafilzadeh

et al. 2023

IET Nanobiotechnology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The cell cycle arrest test was determined using the flow cytometry technique based on the previously reported protocol [22]. Applying this test, the values of HepG2 cells in the sub‐G1 (apoptosis) phase were measured after incubation with IC 50 concentration of specimens.…”

Section: Methodsmentioning

confidence: 99%

“…As a matter of fact, there are two types of DDSs: active or targeted DDSs and passive or non-targeted DDSs. Passive DDSs are based on the EPR effect and cellular uptake of DDS is not targeted while active DDSs refer to ligand-decorated DDSs which can effectively target specific receptors of the target site [22,23]. Ligands are including antibodies, aptamers, hyaluronic acid, folic acid (FA), etc.…”

Section: Introductionmentioning

confidence: 99%

Biopolymer‐based nanoparticles as promising candidate for inducing apoptosis in liver cancer cells

Hoseinzadeh,

Mokhtari,

Kafilzadeh

et al. 2023

Micro & Nano Letters

Self Cite

View full text Add to dashboard Cite

Liver cancer is one of the most common causes of death all around the globe. On the other hand, conventional modalities, such as chemotherapy and surgery, have not been effectively suppressed cancer incidence due to some deficiencies. As a result, a novel folic acid (FA)‐decorated poly lactic‐co‐glycolic acid (PLGA)‐Alginate (Alg) nanocarrier was efficiently developed for active doxorubicin (Dox) delivery to human HepG2 liver cancer cells. The in vitro assays, including cell viability assay (MTT (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide) test), apoptosis, cell cycle arrest, and cellular uptake, were applied to evaluate the cancer cell growth suppression and apoptosis‐inducing ability of the nanocarrier. More than 85% cytotoxicity was attained after 24 h of treatment with 400‐nM concentration of FA‐PLGA‐Dox‐Alg. More than 21% and 61% apoptosis were observed after 24 h of treatment with 100‐nM concentrations of FA‐PLGA‐Dox‐Alg in apoptosis and cell cycle arrest assays. The cellular uptake of the FA‐PLGA‐Alg nanocarrier was about 30% higher than that of the PLGA‐Alg carrier which indicated the cancer cell targeting ability of the FA‐PLGA‐Alg sample. These results have indicated the potential capability of FA‐PLGA‐Dox‐Alg in the inhibition of liver cancer cells.

show abstract

“…Overall, these nanocomplexes were more effective against cancer cells than against normal cells (Michlewska et al, 2023). Khakinahad et al (2022) created a complex nanocarrier for delivery of margetuximab and quercetin into breast cancer cells. The data showed the enhanced expression of apoptotic Bax and Caspase9 genes that lead to apoptosis of breast cancer cells after application of the nanocomplex.…”

Section: Nanocarriers Based On Lipids Amphiphilic Dendrimers and Dend...mentioning

confidence: 99%

Recent advances in multifunctional dendrimer‐based complexes for cancer treatment

Shcharbin,

Zhogla,

Abashkin

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

The application of nanotechnology in biological and medical fields have resulted in the creation of new devices, supramolecular systems, structures, complexes, and composites. Dendrimers are relatively new nanotechnological polymers with unique features; they are globular in shape, with a topological structure formed by monomeric subunit branches diverging to the sides from the central nucleus. This review analyzes the main features of dendrimers and their applications in biology and medicine regarding cancer treatment. Dendrimers have applications that include drug and gene carriers, antioxidant agents, imaging agents, and adjuvants, but importantly, dendrimers can create complex nanosized constructions that combine features such as drug/gene carriers and imaging agents. Dendrimer‐based nanosystems include different metals that enhance oxidative stress, polyethylene glycol to provide biosafety, an imaging agent (a fluorescent, radioactive, magnetic resonance imaging probe), a drug or/and nucleic acid that provides a single or dual action on cells or tissues. One of major benefit of dendrimers is their easy release from the body (in contrast to metal nanoparticles, fullerenes, and carbon nanotubes), allowing the creation of biosafe constructions. Some dendrimers are already clinically approved and are being used as drugs, but many nanocomplexes are currently being studied for clinical practice. In summary, dendrimers are very useful tool in the creation of complex nanoconstructions for personalized nanomedicine.This article is categorized under: Diagnostic Tools > Diagnostic Nanodevices Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Margetuximab conjugated-PEG-PAMAM G4 nano-complex: a smart nano-device for suppression of breast cancer

Cited by 25 publications

References 42 publications

Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells

Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells

Biopolymer‐based nanoparticles as promising candidate for inducing apoptosis in liver cancer cells

Recent advances in multifunctional dendrimer‐based complexes for cancer treatment

Contact Info

Product

Resources

About